Karba R, Mrhar A, Kozjek F, Bremsak F, Kopitar Z, Lenardic A
Eur J Drug Metab Pharmacokinet. 1983;8(1):21-3. doi: 10.1007/BF03189577.
For this study of dihydroergosine pharmacokinetic modelling and simulation, the data from our paper about 3H-DHESN plasma, bile, urine, and faeces concentrations after intravenous and oral administration were used (1). The model obtained with the identified parameters was in agreement with in vivo data. Certain special phenomena, such as the enterohepatic cycle and incomplete absorption, were taken into account. Analog-hybrid simulation and identification represents an effective tool for such studies. In spite of the limited validity of the available in vivo data, the work represents a first step in the introduction of DHESN into human medicine.
在这项关于二氢麦角碱药代动力学建模与模拟的研究中，我们使用了发表于论文中的静脉注射和口服给药后3H-DHESN在血浆、胆汁、尿液和粪便中的浓度数据(1)。通过识别参数获得的模型与体内数据相符。研究考虑了某些特殊现象，如肠肝循环和不完全吸收。模拟混合模拟与识别是此类研究的有效工具。尽管现有体内数据的有效性有限，但这项工作是将DHESN引入人类医学的第一步。
